Presentations and Publications

Media

Presentations & Publications

February 12, 2022

Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Results from the Phase II ALTITUDE™ Study

Michael Klufas, M.D., Retina Service, Wills Eye Hospital, Assistant Professor of Ophthalmology, Thomas Jefferson University

February 9, 2022

RGX-111 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis of Data from the First in Human Study

Raymond Wang, M.D., Division of Metabolic Disorders, CHOC Children's Hospital, Department of Pediatrics, University of California, Irvine, CA

February 9, 2022

RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II (MPS II): Interim Analysis of Data from the First in Human Study

Roberto Giugliani, M.D., Ph.D., Presenter title: Professor, Department of Genetics, UFRGS, Medical Genetics Service, HCPA, Porto Alegre, Brazil

November 12, 2021

Two Year Results from the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of nAMD, and an Update on Suprachoroidal Trials

Robert L. Avery, M.D., Founder of California Retina Consultants and Research Foundation

October 9, 2021

Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE™ Study

Dennis Marcus, M.D., F.A.S.R.S., Southeast Retina Center

October 1, 2021

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results from the Phase II AAVIATE® Study

Nikolas London, M.D., M.S., M.S., F.A.C.S., Partner and Director of Research, Retina Consultants of San Diego, Chief of Ophthalmology, Scripps Memorial Hospital

October 1, 2021

Subretinal Delivery of RGX-314 for Neovascular AMD: End of Phase I/IIa Study Results

Allen Ho, M.D., Director of Retina Research at Wills Eye Hospital and Mid Atlantic Retina

February 8, 2021

RGX-121 Gene Therapy for Severe Mucopolysaccharidosis Type II (MPS II): Interim Results of an Ongoing First in Human Trial

Marie-Laure Névoret, MD – Senior Clinical Development Lead, REGENXBIO

October 11, 2019

Key Takeaways From The RGX-314 Phase I/IIa Clinical Trial For Wet AMD (Cohorts 1-5)

Jeffrey Heier, MD – Ophthalmic Consultants of Boston

October 26, 2018

Six Month Results of the Phase I Study to Evaluate Safety & Tolerability of RGX-314 Gene Therapy in nAMD Subjects

Jeffrey Heier, MD – Ophthalmic Consultants of Boston

Media

Presentations & Publications

Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Results from the Phase II ALTITUDE™ Study

RGX-111 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type I (MPS I): Interim Analysis of Data from the First in Human Study

RGX-121 Gene Therapy for the Treatment of Severe Mucopolysaccharidosis Type II (MPS II): Interim Analysis of Data from the First in Human Study

Two Year Results from the Subretinal RGX-314 Gene Therapy Phase 1/2a Study for the Treatment of nAMD, and an Update on Suprachoroidal Trials

Suprachoroidal Delivery of RGX-314 for Diabetic Retinopathy Without CI-DME: Early Results From the Phase II ALTITUDE™ Study

Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results from the Phase II AAVIATE® Study

Subretinal Delivery of RGX-314 for Neovascular AMD: End of Phase I/IIa Study Results

RGX-121 Gene Therapy for Severe Mucopolysaccharidosis Type II (MPS II): Interim Results of an Ongoing First in Human Trial

Key Takeaways From The RGX-314 Phase I/IIa Clinical Trial For Wet AMD (Cohorts 1-5)

Six Month Results of the Phase I Study to Evaluate Safety & Tolerability of RGX-314 Gene Therapy in nAMD Subjects

SIGN UP

Contact Us

Follow Us

Contact Us

Contact Us

Contact Us

Contact Us

Contact Us

Contact Us